Curr Health Sci J, vol. 49, no. 4, 2023

Stem Cell Treatments in Preclinical Relevant Stroke Models


L.R. Pinosanu(1), N. Wolff(2), D.G. Olaru(3), A.P. Wagner(1)

(1)Experimental Research Center for Normal and Pathological Aging
(ARES), University of Medicine and Pharmacy of Craiova, Craiova, Romania,
(2)University of Crete, School of Sciences, Faculty of Medicine, Heraklion, Crete, Greece,
(3)Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, Romania


Since stroke has limited treatment options, an active search for new therapeutic approaches is required. Initial excitement of using cell-based therapies to stimulate recovery processes in the ischemic brain turned into a more measured perspective, acknowledging obstacles related to the unfavorable environments associated in part with aging. Given the predominance of stroke in older populations, evaluating the effectiveness of cell therapies in aged brain environments is essential and clinically relevant. Despite a common perception of the aged brain being resistant to regeneration, recent research with neural precursor cells and bone marrow-derived mesenchymal stem cells indicates that cell-based therapy can promote plasticity and remodeling in the aged rat brain. However, significant differences in the aged brain compared to the young brain, such as expedited progression of ischemic injury to brain infarction, decreased rate of endogenous neurogenesis, and delayed onset of neurological recovery, must be noted. The effectiveness of cell-based therapies may further be connected to age-related comorbidities such as diabetes or hyperlipidemia, potentially leading to maladaptive or impaired brain remodeling. These age-related factors need careful consideration in the clinical application of restorative therapies for stroke.

Stroke, cell therapy, comorbidities, aging, neurogenesis.

Denissa Greta Olaru, University of Crete, School of Sciences, Faculty of Medicine, Heraklion, Crete, Greece, e-mail:

DOI 10.12865/CHSJ.49.04.02 - Download PDF